Clorox Q1 FY27 diluted EPS more than doubles to $1.39; net sales rise 33% to $1.91 billion
Bitget2026/11/02 21:19- Clorox’s first-quarter FY27 diluted earnings per share more than doubled to $1.39 from a year earlier.
- Net sales climbed 33% to $1.91 billion, benefiting from the GOJO acquisition.
- Gross margin fell to 40.4%, primarily due to higher commodity, manufacturing and logistics costs.
- The business launched Clorox Purell ProCare, combining CloroxPro and GOJO with a unified sales and service organization.
- FY27 diluted earnings per share are still expected between $5.41 and $5.71.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
CleanSpark presents fully funded Sandersville project in investor presentation
Forge Nano completes acquisition of HzO
Crypto prices
More
